首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2056497

疫苗佐劑市場規模、佔有率、趨勢和預測：按產品類型、給藥途徑、疾病、應用和地區分類，2026-2034年

Vaccine Adjuvants Market Size, Share, Trends and Forecast by Product Type, Route of Administration, Diseases, Application, and Region, 2026-2034

出版日期: 2026年06月01日 | 出版商:

IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2025年全球疫苗佐劑市場規模達12.236億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到29.876億美元，2026年至2034年的複合年成長率（CAGR）為10.11%。全球疫苗佐劑市場快速成長的原因包括：感染疾病率上升、免疫學和疫苗技術的顯著進步、人們對罕見疾病的認知不斷提高、未接種疫苗人群對疫苗接種作為應對疫情措施的興趣日益濃厚、政府支出激增以及老年人對有效疫苗的需求。

疫苗佐劑市場趨勢：

疫苗和免疫學技術的進步

免疫學在疫苗佐劑的研發方面取得了顯著進展，新型佐劑的有效性和安全性都超出預期。技術進步使得設計能夠選擇性增強針對特定抗原的免疫反應的佐劑成為可能，從而極大地提高了疫苗對抗全球多種病原體的能力。 2024年2月，艾伯維（AbbVie）和Tentarix Biotherapeutics宣布達成一項多年策略合作協議，共同開發腫瘤學和免疫學領域的生物製藥候選藥物。該協議價值超過6400萬美元。雙方將結合艾伯維在腫瘤學和免疫學領域的專業知識以及Tentarix專有的Tentacles平台，開發針對每個醫學領域中單一靶點具有條件性活性的多特異性生技藥品。這將有助於激活能夠調節疾病路徑並降低通常與特異性療法相關的安全性問題的免疫細胞。

人們對罕見疾病的認知與了解不斷提高

人們對罕見疾病的日益關注，正加速疫苗研發面臨獨特的挑戰。這種新的認知推動了人們對可根據不同相關人員的特定需求量身定做的疫苗佐劑的興趣。在歐盟，罕見疾病被定義為每10萬歐洲人口中患病人數少於50人的疾病。相較之下，美國《孤兒藥法案》將罕見疾病定義為美國患病人數少於20萬人的疾病。其他國家對罕見疾病的定義則差異很大，從剛果每10萬人中患病人數極低的5人，到印度每10萬人中患病人數最高的76人。全球平均而言，罕見疾病每10萬人中患病人數為40人。根據最新估計，全球3,585種罕見疾病的盛行率佔世界人口的3.5%至5.9%，相當於2.63億至4.46億人。

促進全球疫苗接種，以應對流行病的威脅

以新冠肺炎疫情為代表的全球抗疫行動，引發了前所未有的全球疫苗接種運動，也使得疫苗佐劑市場成為公共衛生領域的焦點。此外，疫苗佐劑的主要用途——增強免疫反應、確保疫苗穩定性、提高疫苗效力以及降低疫苗劑量——正在推動市場成長。據美國廣播公司新聞報道，本週新增新冠肺炎住院病例15,141例。根據美國疾病管制與預防中心（CDC）的數據，這一數字與2024年4月初的水平大致相同。然而，這數字低於2022年1月22日當週的尖峰時段，當時每週住院病例高達150,650例，正值奧密克戎株疫情高峰期。 CDC報告稱，自疫情總合新冠肺炎住院治療。

The global vaccine adjuvants market size reached USD 1,223.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 2,987.6 Million by 2034, exhibiting a growth rate (CAGR) of 10.11% during 2026-2034. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie, and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product type, route of administration, diseases, and application.

Breakup by Product Type:

Adjuvant Emulsions
Pathogen Components
Particulate Adjuvants
Combination Adjuvants
Others

Adjuvant Emulsions accounts for the majority of the market share

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

Oral
Intramuscular
Intranasal
Subcutaneous
Intradermal
Others

Intramuscular represents the leading market segment

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

Cancer
Infectious Diseases
Others

Infectious diseases accounts for the majority of the market share

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

Research
Commercial

Research represents the leading market segment

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.
Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Key Questions Answered in This Report

1.What was the size of the global vaccine adjuvants market in 2025?
2.What is the expected growth rate of the global vaccine adjuvants market during 2026-2034?
3.What are the key factors driving the global vaccine adjuvants market?
4.What has been the impact of COVID-19 on the global vaccine adjuvants market?
5.What is the breakup of the global vaccine adjuvants market based on the product type?
6.What is the breakup of the global vaccine adjuvants market based on route of administration?
7.What is the breakup of the global vaccine adjuvants market based on the diseases?
8.What is the breakup of the global vaccine adjuvants market based on the application?
9.What are the key regions in the global vaccine adjuvants market?
10.Who are the key players/companies in the global vaccine adjuvants market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product Type

6.1 Adjuvant Emulsions
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Pathogen Components
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Particulate Adjuvants
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Combination Adjuvants
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Intramuscular
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Intranasal
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Subcutaneous
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Intradermal
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Diseases

8.1 Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Infectious Diseases
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Application

9.1 Research
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Commercial
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Adjuvatis
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
- 15.3.2 Agenus Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 Croda International Plc
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 CSL Limited
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
- 15.3.5 Dynavax Technologies
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 InvivoGen
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Novavax Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 OZ Biosciences
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
- 15.3.9 Phibro Animal Health Corporation
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 SEPPIC
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
- 15.3.11 SPI Pharma
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio

簡介目錄圖表

List of Figures

Figure 1: Global: Vaccine Adjuvants Market: Major Drivers and Challenges
Figure 2: Global: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020-2025
Figure 3: Global: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 4: Global: Vaccine Adjuvants Market: Breakup by Product Type (in %), 2025
Figure 5: Global: Vaccine Adjuvants Market: Breakup by Route of Administration (in %), 2025
Figure 6: Global: Vaccine Adjuvants Market: Breakup by Diseases (in %), 2025
Figure 7: Global: Vaccine Adjuvants Market: Breakup by Application (in %), 2025
Figure 8: Global: Vaccine Adjuvants Market: Breakup by Region (in %), 2025
Figure 9: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market: Sales Value (in Million USD), 2020 & 2025
Figure 10: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 11: Global: Vaccine Adjuvants (Pathogen Components) Market: Sales Value (in Million USD), 2020 & 2025
Figure 12: Global: Vaccine Adjuvants (Pathogen Components) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 13: Global: Vaccine Adjuvants (Particulate Adjuvants) Market: Sales Value (in Million USD), 2020 & 2025
Figure 14: Global: Vaccine Adjuvants (Particulate Adjuvants) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 15: Global: Vaccine Adjuvants (Combination Adjuvants) Market: Sales Value (in Million USD), 2020 & 2025
Figure 16: Global: Vaccine Adjuvants (Combination Adjuvants) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 17: Global: Vaccine Adjuvants (Other Product Types) Market: Sales Value (in Million USD), 2020 & 2025
Figure 18: Global: Vaccine Adjuvants (Other Product Types) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 19: Global: Vaccine Adjuvants (Oral) Market: Sales Value (in Million USD), 2020 & 2025
Figure 20: Global: Vaccine Adjuvants (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 21: Global: Vaccine Adjuvants (Intramuscular) Market: Sales Value (in Million USD), 2020 & 2025
Figure 22: Global: Vaccine Adjuvants (Intramuscular) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 23: Global: Vaccine Adjuvants (Intranasal) Market: Sales Value (in Million USD), 2020 & 2025
Figure 24: Global: Vaccine Adjuvants (Intranasal) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 25: Global: Vaccine Adjuvants (Subcutaneous) Market: Sales Value (in Million USD), 2020 & 2025
Figure 26: Global: Vaccine Adjuvants (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 27: Global: Vaccine Adjuvants (Intradermal) Market: Sales Value (in Million USD), 2020 & 2025
Figure 28: Global: Vaccine Adjuvants (Intradermal) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 29: Global: Vaccine Adjuvants (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
Figure 30: Global: Vaccine Adjuvants (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 31: Global: Vaccine Adjuvants (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
Figure 32: Global: Vaccine Adjuvants (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 33: Global: Vaccine Adjuvants (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
Figure 34: Global: Vaccine Adjuvants (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 35: Global: Vaccine Adjuvants (Other Diseases) Market: Sales Value (in Million USD), 2020 & 2025
Figure 36: Global: Vaccine Adjuvants (Other Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 37: Global: Vaccine Adjuvants (Research) Market: Sales Value (in Million USD), 2020 & 2025
Figure 38: Global: Vaccine Adjuvants (Research) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 39: Global: Vaccine Adjuvants (Commercial) Market: Sales Value (in Million USD), 2020 & 2025
Figure 40: Global: Vaccine Adjuvants (Commercial) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 41: North America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 42: North America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 43: United States: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 44: United States: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 45: Canada: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 46: Canada: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 47: Asia-Pacific: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 48: Asia-Pacific: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 49: China: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 50: China: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 51: Japan: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 52: Japan: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 53: India: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 54: India: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 55: South Korea: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 56: South Korea: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 57: Australia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 58: Australia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 59: Indonesia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 60: Indonesia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 61: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 62: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 63: Europe: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 64: Europe: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 65: Germany: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 66: Germany: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 67: France: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 68: France: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 69: United Kingdom: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 70: United Kingdom: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 71: Italy: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 72: Italy: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 73: Spain: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 74: Spain: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 75: Russia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 76: Russia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 77: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 78: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 79: Latin America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 80: Latin America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 81: Brazil: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 82: Brazil: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 83: Mexico: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 84: Mexico: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 85: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 86: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 87: Middle East and Africa: Vaccine Adjuvants Market: Sales Value (in Million USD), 2020 & 2025
Figure 88: Middle East and Africa: Vaccine Adjuvants Market: Breakup by Country (in %), 2025
Figure 89: Middle East and Africa: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 90: Global: Vaccine Adjuvants Industry: SWOT Analysis
Figure 91: Global: Vaccine Adjuvants Industry: Value Chain Analysis
Figure 92: Global: Vaccine Adjuvants Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Vaccine Adjuvants Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Vaccine Adjuvants Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
Table 3: Global: Vaccine Adjuvants Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
Table 4: Global: Vaccine Adjuvants Market Forecast: Breakup by Diseases (in Million USD), 2026-2034
Table 5: Global: Vaccine Adjuvants Market Forecast: Breakup by Application (in Million USD), 2026-2034
Table 6: Global: Vaccine Adjuvants Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 7: Global: Vaccine Adjuvants Market: Competitive Structure
Table 8: Global: Vaccine Adjuvants Market: Key Players

02-2729-4219

+886-2-2729-4219